Jun 17, 2025
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
Jun 16, 2025
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
Apr 28, 2025
WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY
Mar 31, 2025
WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections
Mar 17, 2025
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
Jan 12, 2025
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
Dec 30, 2024
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
Nov 20, 2024
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
Nov 14, 2024
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating
Nov 11, 2024
WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment
Oct 29, 2024
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
Oct 28, 2024
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
Sep 01, 2024
WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year
Jul 29, 2024
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
Apr 29, 2024
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
Feb 20, 2024
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma
Jan 08, 2024
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Dec 01, 2020
ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy
Nov 18, 2020
WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory
Nov 12, 2020
WuXi Advanced Therapies Expands Services to Include High-Quality and Cost-Effective R&D and GMP Plasmid DNA